SPOTLIGHT: Replydine halts Phase III to conserve cash


Replidyne has stopped enrollment in its Phase III trial of faropenem, a chronic bronchitis treatment. The company said the move is designed to "conserve its cash assets and support initiatives that include pursuing strategic transactions and maintaining its research programs." Replydine's release

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.